Protagonist Therapeutics (PTGX) PT Raised to $90 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts PTGX Hot Sheet
Price: $141.99 +1.88%
Rating Summary:
21 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 13
Rating Summary:
21 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 13
Join SI Premium – FREE
TD Cowen analyst Tara Bancroft raised the price target on Protagonist Therapeutics (NASDAQ: PTGX) to $90.00 (from $65.00) while maintaining a rating.
You May Also Be Interested In
- UBS Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
- Apple (AAPL) PT Raised to $295 at DA Davidson Despite Disappointing Services Growth
- ACI Worldwide (ACIW) PT Raised to $72 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
